Tumor lysis syndrome after capecitabine plus cisplatin treatment in advanced gastric cancer.
Han
Hye-Suk
HS
Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Republic of Korea.
Park
Sook Ryun
SR
Kim
Sun Young
SY
Park
Young Iee
YI
Lee
Jong Seok
JS
Kook
Myeong-Cherl
MC
Choi
Il Ju
IJ
Kim
Chan Gyoo
CG
Lee
Jong Reul
JR
Cho
Soo Jeong
SJ
Kim
Noe Kyeong
NK
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary*; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000378:metabolism; D000069287:Capecitabine; D002945:Cisplatin / Q000009:adverse effects; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives; D006529:Hepatomegaly / Q000209:etiology / Q000628:therapy; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D014057:Tomography, X-Ray Computed; D015275:Tumor Lysis Syndrome / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control / Q000628:therapy*
D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D003841:Deoxycytidine; D000069287:Capecitabine; D002945:Cisplatin; D005472:Fluorouracil